Show simple item record

dc.contributor.authorClarke, Noel W
dc.contributor.authorAli, Adnan
dc.contributor.authorIngleby, FC
dc.contributor.authorHoyle, Alex P
dc.contributor.authorCalvert, J
dc.contributor.authorAttard, G
dc.contributor.authorChowdhury, S
dc.contributor.authorDearnaley, D
dc.contributor.authorDouis, H
dc.contributor.authorGillessen, Silke
dc.contributor.authorJones, R
dc.contributor.authorMalik, Z
dc.contributor.authorMason, MD
dc.contributor.authorMillman, R
dc.contributor.authorParker, C
dc.contributor.authorRush, HL
dc.contributor.authorOmlin, AG
dc.contributor.authorSydes, MR
dc.contributor.authorParmar, MKB
dc.contributor.authorJames, ND
dc.date.accessioned2019-12-09T17:23:32Z
dc.date.available2019-12-09T17:23:32Z
dc.date.issued2019en
dc.identifier.citationClarke NW, Ali A, Ingleby FC, Hoyle A, Calvert J, Attard G, et al. 844O Docetaxel for hormone-naïve prostate cancer: Results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) and sub-group analysis by metastatic burden. Annals of Oncology. 2019;30(Supplement_5).en
dc.identifier.doi10.1093/annonc/mdz248.001en
dc.identifier.urihttp://hdl.handle.net/10541/622602
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz248.001en
dc.titleDocetaxel for hormone-naive prostate cancer: Results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) and sub-group analysis by metastatic burdenen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Departments of Surgery and Urology, The Christie and Salford Royal Hospitals, Manchesteren
dc.identifier.journalAnnals of Oncologyen
refterms.dateFOA2020-01-22T19:57:31Z


Files in this item

Thumbnail
Name:
mdz248.001.pdf
Size:
105.2Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract

This item appears in the following Collection(s)

Show simple item record